Targeted Therapies in Polymyalgia Rheumatica: From Immunopathophysiology to a Redefined Treatment Paradigm. (PubMed, Drugs) - Oct 25, 2026 - "Interleukin-6 receptor blockade with tocilizumab and sarilumab has demonstrated reductions in relapse rates and cumulative GC exposure. A recent randomized controlled trial showed a significant effect of the anti-IL-17A inhibitor secukinumab in achieving sustained remission and reducing GC cumulative dose...This review synthetizes current insights into the immunopathophysiology of PMR and critically appraises emerging targeted treatment strategies, highlighting how these advances may redefine the standard of care. As understanding matures and therapeutic options expand, future management of PMR is likely to shift toward more precise, mechanism-driven approaches, rendering GC-free remission an achievable target for many more patients."
Journal • Immunology • Inflammation • Musculoskeletal Pain • Pain • Polymyalgia Rheumatica • Rheumatology • IFNG • IL17A • IL6R
|
|
Dario Camellino; Elvis Hysa; Marco Amedeo Cimmino
|